10Indexed trials
mesh condition
Carcinoma, Non-Small-Cell Lung
Intelligence
Carcinoma, Non-Small-Cell Lung intelligence: 10 indexed trials, 3 recruiting studies, 6 sponsors across 35 countries.
3Recruiting
6Sponsors
35Countries
Leading sponsors
Merck Sharp & Dohme LLC43 recruiting
Incyte Corporation20 recruiting
Chinese Academy of Medical Sciences10 recruiting
Lisa Sanderson Cox, PhD10 recruiting
NovoCure GmbH10 recruiting
Universitätsmedizin Mannheim10 recruiting
Geographic activity
United States8trials
Spain5trials
Germany4trials
Italy4trials
Israel4trials
Poland4trials
Hungary4trials
Canada3trials
China3trials
Chile2trials
South Korea2trials
France2trials
Leading interventions
Pembrolizumab3trials
Cisplatin2trials
Carboplatin2trials
Epacadostat2trials
Pemetrexed2trials
INCB0011581trials
Best Standard of Care1trials
Camrelizumab, PD-1 monoclonal antibody1trials
Docetetaxel1trials
Gemcitabine1trials
Corticosteroid1trials
Blood Sample Collection1trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.